stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) EBITDA
Alnylam Pharmaceuticals, Inc.'s EBITDA for fiscal 2025 was $557.2M, compared with −$120.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.0B. Over the past ten years it has ranged from −$885.1M (fiscal 2019) to $557.2M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. Alnylam Pharmaceuticals, Inc. ranks 8th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $557.2M | — |
| FY2024 | −$120.2M | — |
| FY2023 | −$228.1M | — |
| FY2022 | −$740.6M | — |
| FY2021 | −$619.0M | — |
| FY2020 | −$754.0M | — |
| FY2019 | −$885.1M | — |
| FY2018 | −$799.4M | — |
| FY2017 | −$488.2M | — |
| FY2016 | −$409.5M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $360.3M | 46.85% |
| Jun 2026 | $245.3M | (13.06%) |
| Mar 2026 | $282.2M | 94.31% |
| Dec 2025 | $145.2M | (61.96%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. | $1.0B |
| EXEL Exelixis, Inc. compare | $1.0B |
| INCY Incyte Corporation compare | $724.9M |
| ASND Ascendis Pharma A/S compare | $321.3M |
| BBIO BridgeBio Pharma, Inc. compare | −$352.4M |
| INSM Insmed, Inc. compare | −$531.4M |
| ROIV Roivant Sciences Ltd. compare | −$593.3M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.1B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement